[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Week in JAMA
April 16, 2008

This Week in JAMA

JAMA. 2008;299(15):1745. doi:10.1001/jama.299.15.1745

Ischemia-reperfusion injury is a significant factor contributing to morbidity and mortality following coronary artery bypass graft (CABG) surgery. Pyridoxal 5′-phosphate monohydrate (MC-1), a naturally occurring pyridoxine metabolite, prevents cellular calcium overload, and some data suggest it may reduce ischemia-reperfusion injury. In the MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery II Trial (MEND-CABG II), intermediate- to high-risk patients undergoing CABG with cardiopulmonary bypass were randomly assigned to receive 250 mg/d of MC-1 or placebo immediately before and for 30 days after surgery. The MEND-CABG II investigators found no difference in the composite outcome of cardiovascular death or nonfatal myocardial infarction among patients who received MC-1 vs placebo during the 30-day follow-up.

×